AbD Serotec and Spinreact Sign Supply Agreement for Antibodies Used
in Clinical Diagnostic Kits
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that its research and diagnostic antibody segment AbD Serotec
and Spinreact S.A., a Spanish biotechnology company with more than 30
years of experience in research and manufacturing of clinical
diagnostic reagents, have signed a supply agreement. Initially, the
agreement covers the use of two antibodies which Spinreact will
incorporate in a series of clinical diagnostic kits. AbD Serotec
will continuously supply Spinreact with antibody material. Financial
details of the agreement were not disclosed.
Dr Josep Puig, Chief Executive Officer of Spinreact, said:
"Spinreact is delighted to announce this agreement with AbD Serotec
- an industry leader in providing tailored antibodies for research
and diagnostic applications. The fast turn-around in antibody
production offered by AbD Serotec, together with the high quality of
the resulting antibodies, will help accelerate the process of
development and validation, allowing Spinreact to bring new clinical
diagnostic reagents for human diseases to the market in the shortest
"Today's news represents another example of the higher value-added
projects that AbD Serotec is increasingly pursuing in line with our
strategy to increase our efforts on the diagnostics side of the
business," commented Dieter Feger, Senior Vice President and Head of
MorphoSys's AbD Serotec unit. "We welcome the decision of Spinreact
to use AbD Serotec antibodies in its clinical diagnostic reagents.
This agreement adds to the growing number of leading diagnostics
companies that have chosen to partner with AbD Serotec to bring
innovative diagnostic solutions to doctors and patients."
Following Swedish diagnostic company Phadia AB, Spinreact is the
second significant diagnostic company to implement antibodies
provided by AbD Serotec into a clinical diagnostic kit.
Meet AbD Serotec at the 2009 AACC Annual Meeting in Chicago, IL, USA
July 19th to 23rd at booth No.: 4132.
For further information please contact: Dr. Claudia Gutjahr-LÃ¶ser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, firstname.lastname@example.org or Mario Brkulj, Senior
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, email@example.com
MorphoSys is a publicly traded biotechnology company focused on the
generation of fully human antibodies as a means to discover and
develop innovative antibody-based drugs against life-threatening
diseases. MorphoSys's goal is to establish HuCAL as the technology of
choice for antibody generation in research, diagnostics and
therapeutic applications. The Company currently has therapeutic and
research alliances with the majority of the world's largest
pharmaceutical companies including Boehringer Ingelheim,
Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these
partnerships, more than 50 therapeutic antibody programs are ongoing
in which MorphoSys participates through exclusive license and
milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market
through its AbD Serotec business unit. The business unit has
operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.
(Oxford). For further information please visit
Spinreact, S.A. is a Concateno group company and is a leader in Latex
reagents and in Haemostasis. We are developing a new project with new
latex particles and human antibodies. Spinreact, is a manufacturer
for in vitro diagnostic reagents and is producing reagents for
Biochemistry, Serology and Immunochemistry. Our introduction in
Concateno group of companies has allowed us to provide the latest
technology for drugs of abuse detection to our customers. Further
information is placed in our website: www.spinreact.com
HuCALÂ®, HuCAL GOLDÂ®, HuCAL PLATINUMÂ® and RapMATÂ® are registered
trademarks of MorphoSys AG
This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.